About the Company
TG Biotech is committed to advancing research and development in pursuit of healthy aging and longevity.
About the Company
TG Biotech is committed to advancing research and development in pursuit of healthy aging and longevity.
About the Company
TG Biotech is committed to advancing research and development in pursuit of healthy aging and longevity.
Company History
2022's ~ NOW
2024
Received Export Excellence Award for surpassing $3M in sales;
recognized as a top-performing exporter.
2023
Actiponin® approved by the U.S. FDA as a New Dietary Ingredient (NDI).
2022
Selected as a “Free Star Company” by Daegu Metropolitan City.
2014's ~ 2021's
2021
Obtained General Food Functionality Label for Actiponin®.
Launched in the Philippines, Thailand, and Malaysia.
2020
Actiponin®, featured by Life Extension (USA) as a Natural Compound (AMPK Activator),
entered Whole Foods Market, a subsidiary of Amazon
2017
Official launch of Actiponin® in the U.S. market.
2014
Domestic launch of Actiponin®.
Patent registration completed in Japan and China.
2013's ~ 2000's
2013
Actiponin® recognized as an Individually Approved Health Functional Food
by the Korean MFDS.
Registered with the U.S. Patent Office.
2012
Completed clinical trials on anti-obesity efficacy of Actiponin®.
2009
Registered Actiponin® as a domestic patent (KR10-0930580).
2007
Developed a body fat improvement ingredient from Dolwoe Leaf Extract.
2006
Featured in YTN’s “Scientists Leading the 21st Century”.
Attracted investment from Korea Development Bank and KDB Capital.
2004
Discovered an obesity-related gene
(IDPc: cytosolic NADP-dependent isocitrate dehydrogenase).
2002
Selected as an INNO-BIZ certified company for innovation.
2000
TG Biotech established on March 20, with initial investment capital secured.
Company History
2022's ~ NOW
2024
Received Export Excellence Award for surpassing $3M in sales;
recognized as a top-performing exporter.
2023
Actiponin® approved by the U.S. FDA as a New Dietary Ingredient (NDI).
2022
Selected as a “Free Star Company” by Daegu Metropolitan City.
2014's ~ 2021's
2021
Obtained General Food Functionality Label for Actiponin®.
Launched in the Philippines, Thailand, and Malaysia.
2020
Actiponin®, featured by Life Extension (USA) as a Natural Compound (AMPK Activator),
entered Whole Foods Market, a subsidiary of Amazon
2017
Official launch of Actiponin® in the U.S. market.
2014
Domestic launch of Actiponin®.
Patent registration completed in Japan and China.
2013's ~ 2000's
2013
Actiponin® recognized as an Individually Approved Health Functional Food
by the Korean MFDS.
Registered with the U.S. Patent Office.
2012
Completed clinical trials on anti-obesity efficacy of Actiponin®.
2009
Registered Actiponin® as a domestic patent (KR10-0930580).
2007
Developed a body fat improvement ingredient from Dolwoe Leaf Extract.
2006
Featured in YTN’s “Scientists Leading the 21st Century”.
Attracted investment from Korea Development Bank and KDB Capital.
2004
Discovered an obesity-related gene
(IDPc: cytosolic NADP-dependent isocitrate dehydrogenase).
2002
Selected as an INNO-BIZ certified company for innovation.
2000
TG Biotech established on March 20, with initial investment capital secured.
Company History
2022's ~ NOW
2024
Received Export Excellence Award for surpassing $3M in sales;
recognized as a top-performing exporter.
2023
Actiponin® approved by the U.S. FDA as a New Dietary Ingredient (NDI).
2022
Selected as a “Free Star Company” by Daegu Metropolitan City.
2014's ~ 2021's
2021
Obtained General Food Functionality Label for Actiponin®.
Launched in the Philippines, Thailand, and Malaysia.
2020
Actiponin®, featured by Life Extension (USA) as a Natural Compound (AMPK Activator),
entered Whole Foods Market, a subsidiary of Amazon
2017
Official launch of Actiponin® in the U.S. market.
2014
Domestic launch of Actiponin®.
Patent registration completed in Japan and China.
2013's ~ 2000's
2013
Actiponin® recognized as an Individually Approved Health Functional Food
by the Korean MFDS.
Registered with the U.S. Patent Office.
2012
Completed clinical trials on anti-obesity efficacy of Actiponin®.
2009
Registered Actiponin® as a domestic patent (KR10-0930580).
2007
Developed a body fat improvement ingredient from Dolwoe Leaf Extract.
2006
Featured in YTN’s “Scientists Leading the 21st Century”.
Attracted investment from Korea Development Bank and KDB Capital.
2004
Discovered an obesity-related gene
(IDPc: cytosolic NADP-dependent isocitrate dehydrogenase).
2002
Selected as an INNO-BIZ certified company for innovation.
2000
TG Biotech established on March 20, with initial investment capital secured.
TG Biotech Co., Ltd.
Head Office: B123, Techno Building, Kyungpook National University, 47, Gyeongdae-ro 17-gil, Buk-gu, Daegu, Republic of Korea
Tel: +82-53-953-0833 | Fax: +82-53-953-0834
© TG Biotech Corporation All Rights Reserved
TG Biotech Co., Ltd.
Head Office: B123, Techno Building, Kyungpook National University, 47, Gyeongdae-ro 17-gil, Buk-gu, Daegu, Republic of Korea
Tel: +82-53-953-0833 | Fax: +82-53-953-0834
© TG Biotech Corporation All Rights Reserved
TG Biotech Co., Ltd.
Head Office: B123, Techno Building, Kyungpook National University, 47, Gyeongdae-ro 17-gil, Buk-gu, Daegu, Republic of Korea
Tel: +82-53-953-0833 | Fax: +82-53-953-0834
© TG Biotech Corporation All Rights Reserved